Xi'an Xintong Pharmaceutical

Xi'an Xintong Pharmaceutical is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative small molecule drugs for liver diseases, including chronic hepatitis B, hepatocellular carcinoma, and non-alcoholic steatohepatitis (NASH). The company utilizes its core HepDirect technology platform, which is designed to deliver drugs specifically to the liver, thereby increasing local concentration and therapeutic efficacy while minimizing systemic side effects. Its lead candidate, pradefovir, is a next-generation prodrug for chronic hepatitis B that has successfully completed Phase 3 clinical trials in China. Beyond hepatology, the company is also expanding its research into cardiovascular and infectious disease treatments. Xi'an Xintong aims to address significant unmet medical needs by providing high-quality, targeted therapies for patients with chronic liver conditions.